{"id":38264,"date":"2023-02-20T19:44:47","date_gmt":"2023-02-20T19:44:47","guid":{"rendered":"https:\/\/dailytalks.org\/?p=38264"},"modified":"2023-02-20T19:44:47","modified_gmt":"2023-02-20T19:44:47","slug":"eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-europe","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=38264","title":{"rendered":"Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer&#8217;s Disease in Europe"},"content":{"rendered":"<p>TOKYO, Jan 11, 2023 &#8211; (JCN Newswire) &#8211;  Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Eisai has submitted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril antibody, for the treatment of early Alzheimer&#8217;s disease (mild cognitive impairment due to Alzheimer&#8217;s disease (AD) and mild AD dementia) to the European Medicines Agency (EMA&#8230;<br \/><a href=\"https:\/\/www.jcnnewswire.com\/pressrelease\/80343\/3\/\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>TOKYO, Jan 11, 2023 &#8211; (JCN Newswire) &#8211; Eisai Co., Ltd. and Biogen Inc. (Nasdaq:<\/p>\n","protected":false},"author":1,"featured_media":38265,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-38264","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-europe"],"featured_image_urls":{"full":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/02\/38264-eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-europe.jpg",240,144,false],"thumbnail":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/02\/38264-eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-europe-150x144.jpg",150,144,true],"medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/02\/38264-eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-europe.jpg",240,144,false],"medium_large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/02\/38264-eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-europe.jpg",240,144,false],"large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/02\/38264-eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-europe.jpg",240,144,false],"1536x1536":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/02\/38264-eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-europe.jpg",240,144,false],"2048x2048":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/02\/38264-eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-europe.jpg",240,144,false],"chromenews-featured":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/02\/38264-eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-europe.jpg",240,144,false],"chromenews-large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/02\/38264-eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-europe.jpg",240,144,false],"chromenews-medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/02\/38264-eisai-submits-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-europe.jpg",240,144,false]},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=16\" rel=\"category\">Europe<\/a>","tag_info":"Europe","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/38264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38264"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/38264\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/media\/38265"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}